Neuromuscular blockade in the management of cerebral palsy

Journal of Child Neurology

Volumn 11, Issue SUPPL. 1, 1996, Pages

  Andrew Koman, L ^a   Mooney III, James F ^a   Smith, Beth Paterson ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BOTULINUM TOXIN A; LOCAL ANESTHETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; PHENOL;

ARTICLE; CEREBRAL PALSY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; HUMAN; LOCAL ANESTHESIA; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL;

EID: 0029907423     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073896011001s04     Document Type: Article

References (44)

1. Hariga J: Influences sur la motricité de la suppression des effecteurs gamma par alcoolisation des nerfs périphériques. Acta Neurol Belg 1966;66:607-611.
2. Hariga J, Tardieu G, Tardieu C, Gagnard L: Effets de l'application d'alcool dilué sur le nerf. Confrontation de l'étude dynamographique de l'étude histologique chez chat décérèbre. Rev Neurol (Paris) 1964;111:472-474.
3. Tardieu G, Tardieu C, Hariga J, Gagnard L: Treatment of spasticity by injection of dilute alcohol at the motor point or by epidural route. Clinical extension of an experiment on the decerebrate cat. Dev Med Child Neurol 1968;10:555-568.
4. Carpenter EB: Role of nerve blocks in the foot and ankle in cerebral palsy: Therapeutic and diagnostic. Foot Ankle 1983;4:164-166.
5. Carpenter EB, Seitz DG: Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol 1980;22:497-501.
6. Yadav SL, Singh U, Dureja GP, et al: Phenol block in the management of spastic cerebral palsy. Indian J Pediatr 1994;61:249-255.
7. Spira R: Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol 1971;13:164-173.
8. Koman LA, Ferrari E, Mubarak S, et al: Botulinum toxin type A (BTA) in the treatment of lower-limb spasticity associated with cerebral palsy. Dev Med Child Neurol 1995;37:19-20.
9. Koman LA, Mooney JF III, Smith B, et al: Management of cerebral palsy with botulimun-A toxin. Preliminary investigation. J Pediatr Orthop 1993;13:489-495.
10. Koman LA, Mooney JF III, Smith BP, et al: Management of spasticity in cerebral palsy with botulinum A toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994;14:299-303.
11. Corry IS, Cosgrove AP, Duffy CM, et al: Botulinum toxin A as an alternative to serial casting in the conservative management of equinus in cerebral palsy. Dev Med Child Neurol 1995;37:20-21.
12. Cosgrove AP, Corry IS, Graham HK: Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-396.
13. Calderon-Gonzalez R, Calderon-Sepulveda RF, Rincon-Reyes M, et al: Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 1994;10:284-288.
14. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG: Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-D motion analysis study. Dev Med Child Neurol 1995;37:17-18.
15. Wall SA, Chait LA, Temlett JA, et al: Botulinum A toxin chemodenervation: A new modality in cerebral palsied hands. Br J Plast Surg 1993;46:703-706.
16. Reimers J: Functional changes in the antagonists after lengthening of the agonists in cerebral palsy. I. Triceps surae lengthening. Clin Orthop 1990;253:30-34.
17. Reimers J: Functional changes in the antagonists after lengthening the agonists in cerebral palsy. II. Quadriceps strength before and after distal hamstring lengthening. Clin Orthop 1990;253:35-37.
18. Calderon-Gonzalez R, Calderon-Sepulveda RF: Pathophysiology of spasticity and the role of botulinum toxin in its treatment. Acta Neuropediatr 1994;1:45-57.
19. Bleck EE: Orthopaedic Management in Cerebral Palsy. Clinics in Developmental Medicine 99. Philadelphia, JB Lippincott, 1987.
20. Botte AU, Keenan MAE: Percutaneous phenol blocks of the pectoralis major muscle to treat spastic deformities. J Hand Surg 1988;13A:147-149.
21. Braun RM, Hoffer MM, Mooney V, et al: Phenol nerve block in the treatment of acquired spastic hemiplegia in the upper limb. J Bone Joint Surg 1973;55A:580-585.
22. Garland DE, Lucie RS, Waters RL: Current uses of open phenol block for adult acquired spasticity. Clin Orthop 1982;165:217-222.
23. Kelly RE, Gautier-Smith PC: Intrathecal phenol in the treatment of reflex spasms and spasticity. Lancet 1959;2:1102-1105.
24. Khalili AA, Hammel MH, Forster J, Benton JG: Management of spasticity by selective peripheral nerve block with dilute phenol solutions in clinical rehabilitation. Arch Phys Med Rehabil 1964;45:513-519.
25. Moore TJ, Anderson RB: The use of open phenol blocks to the motor branches of the tibial nerve in adult acquired spasticity. Foot Ankle 1991;11:219-221.
26. Wood KM: The use of phenol as a neurolytic agent: A review. Pain 1978;5:205-229.
27. Mooney V, Frykman G, McLamb J: Current status of intraneural phenol injections. Clin Orthop 1969;63:122-131.
28. Jankovic J: Botulinum toxin in movement disorders. Curr Opin Neurol 1994;7:358-366.
29. Scott AB, Kennedy RA, Stubbs HA: Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-350.
30. Quinn N, Hallett M: Dose standardization of botulinum toxin. Lancet 1989;1:964.
31. Schantz EJ, Johnson EA: Dose standardization of botulinum toxin. Lancet 1990;335:421.
32. Kao I, Drachman DB, Price DL: Botulinum toxin: Mechanism of presynaptic blockade. Science 1976;193:1256-1258.
33. Melling J, Hambleton P, Shone CC: Clostridium botulinum toxins: Nature and preparation for clinical use. Eye 1988;2:16-23.
34. Scott AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-770.
35. Duchen LW: Changes in the electron microscopic structure of slow and fast skeletal muscle fibers of the mouse after the local injection of botulinum toxin. J Neurol Sci 1971;14:61-74.
36. Lange DJ, Brin MF, Fahn S, Lovelace RE: Distant effects of locally injected botulinum toxin - incidence and course. Adv Neurol 1988;50:609-613.
37. Lange DJ, Brin MF, Warner CL, et al: Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-555.
38. Sanders DB, Massey EW, Buckley EG: Botulinum toxin for blepharospasm: Single-fiber EMG studies. Neurology 1986;36:545-547.
39. Scott AB, Suzuki D: Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3:333-335.
40. Borodic GE, Cozzolino D: Blepharospasm and its treatment, with emphasis on the use of botulinum toxin. Plast Reconstr Surg 1989;83:546-554.
41. Borodic GE, Pearce B: Antibodies to botulinum toxin, letter. Neurology 1995;45:204.
42. Zuber M, Sebald M, Bathien N, et al: Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993;43:1715-1718.
43. Koman LA, Mooney JF, Smith BP: Management of cerebral palsy with botulinum A toxin: A randomized, double-blind study. Dev Med Child Neurol 1992;34:23.
44. Koman LA, Mooney JF, Mulvaney T, et al: Further evaluation of botulinum A toxin (Botox) in the management of cerebral palsy. Dev Med Child Neurol 1993;35:29.